EW

Edwards Lifesciences Corp.

HALAL — FINANCIAL SCREENS PASSstock

Is EW Halal?

Life-preserving heart-valve and critical-care devices are generally permissible, and the current asset-based financial ratios pass while product-specific questions remain.

What You Should Know

Edwards Lifesciences' March 31, 2026 filing reports debt/assets of 4.49%, cash plus identifiable debt securities/assets of 27.90%, receivables plus cash/assets of 25.66% and disclosed net interest income/revenue of 2.03%. Its transcatheter and surgical heart valves and critical-care technologies generally support preservation of life, while bovine tissue, clinical use, access and acquisition exposure require qualitative review.

⚠️ Concerns

  • Some heart valves use bovine pericardial tissue; necessity and transformation are scholar- and product-specific
  • Net interest income is disclosed but no universal purification percentage is prescribed
  • The Autus acquisition and investment impairments can change product and financial exposure
  • Clinical evidence, safety, access, pricing and regulatory obligations require continuing review

Current quantitative Sharia screen

Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-13.

USD · millions
Interest-bearing debt / assets
4.49%Within limit
Below 33.333% under FTSE Yasaar

598.5 / 13,321.2

Cash + interest-bearing securities / assets
27.89%Within limit
Below 33.333% under FTSE Yasaar

3,715.6 / 13,321.2

Receivables + cash / assets
25.66%Within limit
Below 50% under FTSE Yasaar

3,418.5 / 13,321.2

Non-compliant income / revenue
2.03%Within limit
No more than 5% under FTSE Yasaar

33.5 / 1,648.6

FTSE Yasaar
v4.6, February 2026
Financial
Pass
Overall
Incomplete

Debt is 4.49%, cash plus identifiable debt securities are 27.90%, receivables plus cash are 25.66% and disclosed net interest income is 2.03%; the examined financial ratios pass, while product materials and clinical-use questions remain qualitatively incomplete.

MSCI Islamic (total-assets series)
October 2024 methodology
Financial
Pass
Overall
Incomplete

Debt is 4.49%, liquidity is 27.90% and receivables plus cash are 25.66%, below the examined MSCI total-assets limits. This is a calculation against the named method, not an index-membership claim.

Malaysia SAC financial ratios
single 5% activity benchmark adopted November 2025
Financial
Pass
Overall
Incomplete

Debt is 4.49% and liquidity is 27.90%, below the examined Malaysia SAC financial limits. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security.

Market-cap denominator methods
MSCI M-Series, S&P and Dow Jones methods differ
Financial
Not calculated
Overall
Not calculated

A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.

Business-activity disclosure

Edwards Lifesciences develops transcatheter and surgical heart valves, transcatheter mitral and tricuspid therapies and critical-care technologies. Medical devices that treat disease and preserve life are generally permissible, while animal-derived materials, clinical use and product-specific evidence require continuing review.

Limitation: The filing does not allocate revenue by biological material, procedure, clinical use or customer contract into a universal prohibited-revenue numerator; no blanket zero-concern claim is made.

Purification

Edwards discloses net interest income but does not prescribe a scholar-approved purification percentage. Readers should follow the qualified scholar or methodology they use rather than applying an invented fixed rate.

Inputs, assumptions and primary sources
  • Inputs use Edwards Lifesciences' March 31, 2026 Form 10-Q; amounts are USD millions as presented in the filing.
  • Debt uses the $598.5 million carrying value of the 4.3% senior notes; no revolving-credit balance was outstanding. Operating lease liabilities are not entered as conventional debt.
  • Cash uses $2,445.5 million of cash and cash equivalents. Interest-bearing securities use $1,270.1 million of disclosed debt securities, including held-to-maturity bank time deposits and available-for-sale commercial paper, government and agency, asset-backed and corporate debt securities.
  • Receivables use $775.7 million of accounts receivable plus $197.3 million of other receivables reported on the balance sheet.
  • Quarterly net sales are $1,648.6 million and disclosed net interest income is $33.5 million. No fixed purification percentage is prescribed.

This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.

🧾
Own EW? Purify your portfolio.
Per-holding purification amounts, zakat on your shares, and halal alternatives for flagged holdings — a personalized report prepared for you within 48 hours.
Order Your Report — $49 →
Track EW and 30,000+ stocks' live compliance status with Islamicly — 50% off with code ZAKAT50.Get Islamicly →

Want to screen more assets?

Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.

Go to Halal Checker →